Zanzalintinib for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Oct 2023: Trial registered, NCT06082167
  2. 7 Jun 2024: Trial started, NCT06082167

The trials

NCT06082167: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

State
Under way
Phase
Phase 2 and Phase 3
People
600 planned
Started
7 Jun 2024
Primary completion
Aug 2028
Arms
Zanzalintinib + Pembrolizumab
Results
None posted
  1. 13 Oct 2023: Trial registered
  2. 7 Jun 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.